| Literature DB >> 23977126 |
Martin Reist1, Nadine Geser, Herbert Hächler, Sara Schärrer, Roger Stephan.
Abstract
During the past decade extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae have become a matter of great concern in human and veterinary medicine. In this cross-sectional study fecal swabs of a geographically representative number of Swiss cattle at slaughterhouse level were sampled i) to determine the occurrence of ESBL producing Enterobacteriaceae in the Swiss slaughter cattle population younger than 2 years, and ii) to assess risk factors for shedding ESBL producing Enterobacteriaceae. In total, 48 (8.4%; 95% C.I. 6.3-11.1%) independent ESBL producing Enterobacteriaceae were detected among the 571 tested animals. Species identification revealed 46 E. coli strains, one Enterobacter cloacae and one Citrobacter youngae. In view of beta-lactam antibiotics, all 48 isolates were resistant to ampicillin, cephalothin and cefpodoxime. Forty-five (93.8%) isolates were resistant cefuroxime; one (2.1%) isolate to cefoxitin, 28 (58.3%) isolates to cefotaxime, 2 (4.2%) isolates to ceftazidime, and 2 (4.2%) isolates to cefepime. Risk factors for shedding ESBL producing Enterobacteriaceae were (i) age (OR 0.19 and 0.12 in age category 181 d to 1 y and 1 y to 2 y compared to ≤180 d), (ii) primary production type, meaning dairy compared to beef on farm of origin (OR 5.95), and (iii) more than 1 compared to less than 1 animal movement per d per 100 animals on farm of origin (OR 2.37).Entities:
Mesh:
Substances:
Year: 2013 PMID: 23977126 PMCID: PMC3748101 DOI: 10.1371/journal.pone.0071725
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of risk factors studied in univariate and multivariate logistic regression models.
| Risk factor | Category | Number of animals | Proportion of positive samples |
| Age Class | ≤180 d | 248 | 15.7% |
| 181 d–1 y | 148 | 3.4% | |
| >1 y | 175 | 2.3% | |
| Production Type | Meat | 244 | 2.5% |
| Dairy | 327 | 12.8% | |
| Number of cattle on farm | ≤30 | 173 | 6.4% |
| 31–60 | 211 | 8.1% | |
| >60 | 187 | 10.7% | |
| Animal movements to farm | ≤0.5 | 428 | 6.3% |
| per day | >0.5 | 143 | 14.7% |
| Animal movements to farm | ≤1/d/100 animals | 461 | 6.9% |
| per day per 100 animals | >1/d/100 animals | 110 | 14.6% |
| Number of animals dying | 0 | 235 | 10.2% |
| on farm per 100 days | ≤1/100 d | 185 | 4.3% |
| >1/100 d | 151 | 10.6% | |
| Number of animals dying on | 0 | 235 | 10.2% |
| farm per 100 days per 100 | ≤2/100 d | 200 | 4.0% |
| animals | >2/100 d | 136 | 11.8% |
Prevalences of animals with ESBL positive isolates.
| No. positives | No. negatives | prevalence | 95% confidence interval | |
| Total | 48 | 523 | 8.41% | 6.32–11.07% |
| ≤180 d | 39 | 209 | 15.73% | 11.55–21.00% |
| 181 d–1 y | 5 | 143 | 3.38% | 1.25–8.12% |
| >1 y | 4 | 171 | 2.29% | 0.73–6.12% |
| Meat | 6 | 238 | 2.46% | 1.00–5.53% |
| Dairy | 42 | 285 | 12.84% | 9.51–17.08% |
| ≤1 mv./d/100 animals | 32 | 429 | 6.94% | 4.87–9.76% |
| >1 mv./d/100 animals | 16 | 94 | 14.55% | 8.80–22.85% |
95% confidence interval with Yates' continuity correction.
Farm level risk factors for ESBL shedding.
| Risk factor | OR | 95% Conf. Int. | p-value | ||
| Prod. type | meat | 1.00 | |||
| dairy | 5.95 | 2.48 - | 14.30 | <0.001 | |
| Movements | ≤1/d/100 anim. | 1.00 | |||
| >1/d/100 anim. | 2.37 | 1.23 - | 4.57 | 0.010 | |
Multivariate logistic regression model.
Animal level risk factors for ESBL shedding.
| Risk factor | OR | 95% Conf. Int. | p-value | ||
| Age | ≤180 d | 1.00 | |||
| 181 d–1 y | 0.19 | 0.07 - | 0.49 | <0.001 | |
| >1 y | 0.12 | 0.04 - | 0.36 | <0.001 | |
Logistic regression model.
Figure 1Characteristics and antimicrobial susceptibility profiles of ESBL-producing Enterobacteriaceae isolated from cattle younger than 2
years. Symbols: black square, positive result or resistant to a specific antimicrobial agent; white square, negative result or susceptible to a specific antimicrobial. Abbreviations: AM, ampicillin (resistant ≤13 mm); AMC, amoxicillin-clavulanic acid (resistant ≤13 mm); CF, cephalothin (resistant ≤14 mm); CXM, cefuroxime (resistant ≤14 mm); FOX, cefoxitin (resistant ≤14 mm); CPD, cefpodoxime (resistant ≤17 mm); CTX, cefotaxime (resistant ≤14 mm); CAZ, ceftazidime (resistant ≤14 mm); FEP, cefepime (resistant ≤14 mm); GM, gentamicin (resistant ≤10 mm); S, streptomycin (resistant ≤11 mm); SXT, trimethoprim-sulfamethoxazole (resistant ≤10 mm); TE, tetracycline (resistant ≤11 mm); NA, nalidixic acid (resistant ≤13 mm); CIP, ciprofloxacin (resistant ≤15 mm); C, chloramphenicol (resistant ≤12 mm). Discrimination between “susceptible” and “resistant” was strictly according to CLSI interpretive criteria. It should be noted, however, that for clinical and therapeutic purposes, ESBL producers should generally be reported resistant to cephalosporins of all 4 generations and monobactams.